Vitamin D3-driven signals for myeloid cell differentiation—Implications for differentiation therapy

Philip Hughes, E Marcinkowska, E Gocek, GP Studzinski, Geoffrey Brown

Research output: Contribution to journalArticle

47 Citations (Scopus)


Primitive myeloid leukemic cell lines can be driven to differentiate to monocyte-like cells by 1 alpha,25-dihydroxyvitaminD(3) (1,25(OH)(2)D-3), and, therefore, 1,25(OH)(2)D-3 may be useful in differentiation therapy of myeloid leukemia and myelodysplastic syndromes (MDS). Recent studies have provided important insights into the mechanism of 1,25(OH)(2)D-3-stimulated differentiation. For myeloid progenitors to complete monocytic differentiation a complex network of intracellular signals has to be activated and/or inactivated in a precise temporal and spatial pattern. 1,25(OH)(2)D-3 achieves this change to the 'signaling landscape' by (i) direct genomic modulation of the level of expression of key regulators of cell signaling and differentiation pathways, and (ii) activation of intracellular signaling pathways. An improved understanding of the mode of action of 1,25(OH)(2)D-3 is facilitating the development of new therapeutic regimens. (C) 2009 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)553-565
Number of pages13
JournalLeukemia Research
Publication statusPublished - 6 Oct 2009


  • Leukemia
  • Differentiation therapy
  • Cell signaling
  • Vitamin D-3
  • Deltanoids


Dive into the research topics of 'Vitamin D3-driven signals for myeloid cell differentiation—Implications for differentiation therapy'. Together they form a unique fingerprint.

Cite this